Resverlogix Corp. is a Canada-based clinical stage biotechnology company. The Company is engaged in developing compounds involving ApoA-I production. The Company’s RVX-208 is a molecule, developed for the treatment of clinical conditions, including atherosclerosis, Diabetes Mellitus and Alzheimer’s disease. RVX-208 is the first bromodomain and extra terminal domain (BET) inhibitor in clinical trials. New compounds arising from Company's epigenetic drug development platform function by inhibiting BET bromodomains and have the potential to impact multiple diseases, including neurodegenerative diseases and diabetes mellitus. The Company’s clinical cardiovascular programs include cardiovascular disease and atherosclerosis, Apoa-I, HDL and reverse cholesterol transport, and RVX-208 and MOA.